COGNITION THERAPEUTICS INC: An Investor’s Guide

I’ve put together this guide to help you understand how Cognition Therapeutics performed this past year. My goal is to translate their recent filings into plain English so you can decide if this company fits your investment strategy.

1. What does this company do?

Cognition Therapeutics is a research-stage drug company focused on the sigma-2 receptor complex. Their lead drug, zervimesine (CT1812), is an oral pill designed to clear toxic proteins from brain cells, which scientists believe are a primary cause of Alzheimer’s disease.

They are currently running several Phase 2 clinical trials, including the SHINE and SEQUEL studies. Because they are still in the research phase, they have not yet generated revenue from product sales.

2. Financial performance: The "Burning Cash" Phase

Cognition Therapeutics operates at a loss as they fund their clinical trials. For 2023, the company reported a loss of $46.8 million, compared to $42.5 million in 2022. The vast majority of these funds are directed toward research and development.

As of late 2023, the company held $45.6 million in cash and short-term investments. Management has indicated that these funds are expected to support operations through the second half of 2024, meaning the company will need to secure additional capital to continue its research programs.

3. Major wins and challenges

Clinical trials are capital-intensive. To fund these operations, the company has utilized equity offerings. In 2023, they raised $12.3 million through the sale of stock. While this provides necessary operating cash, it also increases the total number of shares outstanding—growing from 25.8 million in 2022 to 34.6 million in 2023—which dilutes the ownership percentage of existing shareholders.

On the positive side, the company secured a $30 million grant from the National Institute on Aging. This non-dilutive funding supports their research efforts without requiring the issuance of additional shares.

4. Financial health and risks

The company has noted a "going concern" risk, which highlights the necessity of securing additional funding to maintain operations.

Key risks to watch:

• The "All-or-Nothing" Gamble: CT1812 is their only clinical-stage drug. If these trials do not produce positive results, the company lacks other advanced projects to offset the impact on their valuation.
• Nasdaq Listing: To remain on the Nasdaq, the company must maintain a share price above $1.00 and meet specific equity requirements. Failure to meet these standards could lead to delisting, which would significantly complicate future fundraising efforts.
• Competition: The company competes against major pharmaceutical firms with significantly larger budgets and established market infrastructure.
• Manufacturing: They rely on third-party manufacturers. Any supply chain disruptions or failures to meet quality standards could lead to costly delays in their clinical trials.

5. Future outlook

The next 12 to 18 months are a critical window for the company. Investors should monitor the results from their Phase 2 trials, as these outcomes will determine the company's ability to advance to Phase 3 or attract a strategic partner. The company’s long-term viability depends on their ability to successfully raise capital or secure further government grants before their current cash reserves are exhausted.

Final Thought for Investors: This is a high-risk, high-reward opportunity typical of early-stage biotech. Because the company is entirely dependent on the success of a single drug candidate and requires frequent capital raises, it is best suited for investors who are comfortable with significant volatility and the possibility of total loss in exchange for the potential of a breakthrough in Alzheimer’s treatment.